Cerdulatinib (PRT062070)

Catalog No.S3566 Batch:S356601

Print

Technical Data

Formula

C20H27N7O3S

Molecular Weight 445.54 CAS No. 1198300-79-6
Solubility (25°C)* In vitro DMSO 89 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively, also inhibits19 other tested kinases with IC50 less than 200 nM.
Targets
JAK2 [1]
(Cell-free assay)
JAK3 [1]
(Cell-free assay)
JAK1 [1]
(Cell-free assay)
6 nM 8 nM 12 nM

Protocol (from reference)

Selleck's Cerdulatinib (PRT062070) has been cited by 7 publications

Targeting TYK2 alleviates Rab27A-induced malignant progression of non-small cell lung cancer via disrupting IFNα-TYK2-STAT-HSPA5 axis [ NPJ Precis Oncol, 2024, 8(1):74] PubMed: 38521810
Naegleria fowleri Extracellular Vesicles Induce Proinflammatory Immune Responses in BV-2 Microglial Cells [ Int J Mol Sci, 2023, 24(17)13623] PubMed: 37686429
A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome [ Cells, 2023, 12(9)1295] PubMed: 37174695
A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome [ Cells, 2023, 12(9)1295] PubMed: 37174695
Naegleria fowleri Extracellular Vesicles Induce Proinflammatory Immune Responses in BV-2 Microglial Cells [ Int J Mol Sci, 2023, 24(17)13623] PubMed: 37686429
Antiviral activity of extracellular vesicles derived from respiratory syncytial virus-infected airway epithelial cells [ Front Immunol, 2022, 13:886701] PubMed: 36032066
Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition [ Int J Mol Sci, 2022, 23(23)14706] PubMed: 36499034

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.